m6A Writers, Readers and Erasers: Mapping and Testing RNA Modification Function
Introduction: Three Proteins, Three Kinds of Claim
m6A is written, read, and erased:
- • Writers — METTL3 with METTL14 in a core complex, with WTAP for targeting and additional adaptors.
- • Erasers — FTO and ALKBH5, with distinct substrate preferences and tissue distributions.
- • Readers — YTH-domain proteins (YTHDF1–3, YTHDC1–2), IGF2BP family, HNRNP family members, and others that bind with different structural consequences.
Each class supports a different kind of statement. A writer knockout tells you what the modification does globally; a reader perturbation tells you which downstream function is engaged; an eraser perturbation tells you about reversibility. Treating them as interchangeable is the most common conceptual error in the field — and it is why so many papers report a phenotype without a mechanism.
Part 1 — The Machinery, With Its Complications
| Component | Role | Complication |
|---|---|---|
| METTL3 | Catalytic subunit | Essential; knockout is often lethal or severely growth-impairing |
| METTL14 | Structural partner, RNA binding | Knockout phenotypes can differ from METTL3 loss in magnitude |
| WTAP | Targeting and complex stability | Loss reduces m6A indirectly by destabilizing the complex |
| METTL16 | Distinct subset of sites (e.g., U6, some mRNAs) | Not a general m6A writer; separate biology |
| FTO | Eraser, also acts on other substrates | Broad substrate range complicates interpretation |
| ALKBH5 | Eraser, nuclear | Knockout increases m6A at a subset of sites |
| YTHDF1–3 | Cytoplasmic readers | Partially redundant; effects on stability and translation differ by context |
| YTHDC1 | Nuclear reader | Splicing and export effects |
| IGF2BP1–3 | Stability-promoting readers | Distinct from YTHDF-mediated decay |
Two practical consequences. First, writer knockouts are pleiotropic: m6A is on thousands of transcripts, so a phenotype is not attributable to any one site without site-level work. Second, reader redundancy means single reader knockouts frequently give weak phenotypes even where the mark is functionally important.
Part 2 — Mapping: Choosing a Method by Question
| Method | Resolution | Strength | Limitation |
|---|---|---|---|
| MeRIP-seq (m6A-IP) | ~100 nt peaks | Accessible, transcriptome-wide | Antibody-dependent; no single-base resolution; poor stoichiometry |
| miCLIP / m6A-CLIP | Near single base | High resolution | Specialized, low throughput |
| m6A-REF-seq / DART-seq | Base-adjacent | Antibody-independent options | Enzyme- or APOBEC-dependent biases |
| SELECT / site-specific assays | Single site | Quantitative at a locus | Targeted; not discovery-scale |
| Direct RNA sequencing | Single molecule | Detects modifications natively | Depth and analysis maturity vary |
The practical rule: use MeRIP for discovery, and a targeted quantitative assay for the sites you intend to make claims about. A MeRIP peak is a candidate list entry, not a measured methylation fraction.
Stoichiometry deserves particular attention. Many sites are methylated on a small fraction of transcripts, and low-stoichiometry sites rarely support large phenotypes. Reporting methylation fraction where possible changes how a result should be interpreted.
Part 3 — Reading: What Each Reader Does
Readers convert the mark into an outcome. Their functions are context-dependent and partially overlapping:
- • YTHDF proteins are associated with both decay and translation promotion depending on context and paralogue; the early simple model has been revised repeatedly.
- • IGF2BP proteins typically stabilize their targets.
- • YTHDC1 influences splicing and nuclear export.
- • HNRNP family members can act as structural switches, altering local RNA structure and protein binding.
Because of this heterogeneity, "m6A promotes translation" or "m6A destabilizes RNA" are not general statements. The correct formulation names the reader, the cell type, and the transcripts.
Part 4 — Functional Testing: A Sequence
- Global perturbation first (METTL3 knockdown or knockout, FTO/ALKBH5 manipulation) to establish that the pathway matters in your system, with the caveat that the effect is pleiotropic.
- Identify the transcripts affected by combining m6A mapping with expression and stability data.
- Site-level perturbation at a candidate site: motif editing to prevent methylation, or targeted recruitment of a writer or eraser.
- Measure the intervening mechanism — stability, translation, splicing, or export — with an assay matched to the proposed model.
- Rescue by restoring the methylatable sequence or the writer, showing the phenotype tracks the mark rather than the edit.
Step 3 is where most studies stop short, and it is the step that the pillar's site-level workflow addresses in detail.
Part 5 — Controls That Distinguish Mark From Sequence
- • Catalytically inactive METTL3 in the same configuration, to separate scaffolding from methylation.
- • Motif variant that changes sequence but should not eliminate methylation capacity, to control for sequence effects.
- • Reader knockout or binding mutant, to test whether the effect runs through the reader.
- • Global versus site-specific comparison, so the reader can see whether the phenotype is mark-wide or locus-specific.
- • Matched clones, given that writer manipulation often changes growth rate.
The first two are the ones that make an m6A claim mechanistic rather than correlative.
Part 6 — Where the Field's Claims Are Weakest
Three recurring overstatements, presented with the experiment that would fix each:
| Overstatement | What would support it |
|---|---|
| "m6A at this site stabilizes the mRNA" | Site-level methylation removal plus stability measurement plus rescue |
| "METTL3 promotes translation of gene X" | Reader-dependence shown, plus translation assay at the specific transcript |
| "FTO inhibition is a therapeutic strategy" | Site-level evidence and selectivity data; FTO has other substrates |
The third is a reminder that eraser biology is complicated by substrate promiscuity, which is often omitted from pharmacological claims.
Need m6A sites tested rather than mapped?
EDITGENE builds the toolchain: isogenic motif-edited lines at candidate sites, dCas9–METTL3 and eraser-recruitment lines, catalytically dead writer controls, and stability or translation readouts matched to the proposed mechanism.
Tell us the site, the transcript, and the phenotype. Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
Writer, reader and eraser functions are context-dependent and under active revision; assignments described here reflect current literature and should be verified in the system of interest.
m6A maps are correlative. Mechanistic claims require site-level perturbation, a matched intervening assay, and controls that separate sequence effects from modification effects.
Selected references for further reading
- • Zaccara S, et al. Reading, writing and erasing mRNA methylation. Nature Reviews Molecular Cell Biology. 2019;20:608–624.
- • Dominissini D, et al. Topology of the human and mouse m6A RNA methylomes. Nature. 2012;485:201–206.
- • Meyer KD, et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3′ UTRs and near stop codons. Cell. 2012;149:1635–1646.
- • Liu N, et al. N6-methyladenosine-dependent RNA structural switches regulate RNA–protein interactions. Nature. 2015;518:560–564.
- • Zaccara S, Jaffrey SR. A unified model for the function of YTHDF proteins in regulating m6A-modified mRNA. Cell. 2020;181:1582–1595.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »